Last reviewed · How we verify
CaCP29
CaCP29 is a monoclonal antibody targeting the complement system.
CaCP29 is a monoclonal antibody targeting the complement system. Used for Treatment of Hidradenitis Suppurativa.
At a glance
| Generic name | CaCP29 |
|---|---|
| Also known as | IFX-1 |
| Sponsor | InflaRx GmbH |
| Drug class | Complement inhibitor |
| Target | C5aR1 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CaCP29 works by inhibiting the complement system, which plays a key role in inflammation and immune responses. By targeting the complement system, CaCP29 aims to reduce inflammation and prevent tissue damage.
Approved indications
- Treatment of Hidradenitis Suppurativa
Common side effects
- Injection site reactions
Key clinical trials
- Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum (PHASE2)
- Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. (PHASE2)
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA (PHASE2)
- Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (PHASE2)
- Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction (PHASE2)
- Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CaCP29 CI brief — competitive landscape report
- CaCP29 updates RSS · CI watch RSS
- InflaRx GmbH portfolio CI